Feasibility Study of the FARAFLEX Mapping and PFA System

NARecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

February 15, 2027

Study Completion Date

September 15, 2027

Conditions
Atrial FibrillationPersistent Atrial Fibrillation
Interventions
DEVICE

Ablation Treatment

Subjects scheduled to undergo endocardial mapping and ablation therapy in the treatment of persistent atrial fibrillation or paroxysmal atrial fibrillation. Ablation of the pulmonary veins will be performed; ablation of the left atrial posterior wall, mitral isthmus (MI), LA roof line and/or cavo-tricuspid isthmus (CTI) is at the discretion of the investigator.

Trial Locations (2)

Unknown

RECRUITING

Klinicki bolnicki centar Split, Split

RECRUITING

Nemocnice Na Homolce Hospital, Prague

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY

NCT06510556 - Feasibility Study of the FARAFLEX Mapping and PFA System | Biotech Hunter | Biotech Hunter